Karsten Zieger
Karsten Zieger has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Lars Dyrskjøt
Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark
3 shared publications - Torben Falck Ørntoft
Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark
2 shared publications - Anne Sofie Brems-Eskildsen
Department of Oncology, University Hospital Aarhus, Aarhus, Denmark
1 shared publication - Carsten Wiuf
Department of Mathematical Sciences, University of Copenhagen
1 shared publication - Cherie L. Holcomb
Human Genetics, Roche Molecular Systems, Inc., Pleasanton, CA, USA
1 shared publication - Francisco Mansilla
Department of Molecular Medicine, Aarhus University Hospital, Skejby, 8200 Aarhus N, Denmark
1 shared publication
Latest Publications
- 27 July 2011
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 45 (6) , 411-418
Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette–Guérin immunotherapy on the outcome
Objective. This study aimed to determine the long-term risk of cancer progression of carcinoma in situ (CIS) of the urinary bladder, and whether intravesical bacille Calmette–Guérin (BCG) immunotherapy can reduce the risk of progression of CIS.Material and methods. From a prospectively enrolled cohort of bladder cancer patients treated at Århus University Hospital Skejby, Denmark, between 1994 and 2008, all 163 cases with CIS in the bladder, and a history free of invasive bladder cancer (stage T1–4) at least 1 year prior to inclusion were included in the study. Results. Median follow-up was 51 (0–253) months for progression. Initial treatment consisted of transurethral resection (TUR) alone (109 patients) or TUR plus BCG (54 patients). Twenty-eight patients underwent delayed treatment with BCG. Twenty-one patients in the TUR-alone group (19%) and 42 BCG-treated patients (51%) were free of disease at the end of follow-up (p < 0.001). Progression occurred in 18 BCG-treated patients (22%) versus 31 patients (41%) treated by TUR alone. The 10-year progression-free survival was 62% overall, 50% without BCG and 71% after BCG treatment (p = 0.04). BCG reduced the risk of progression by 46% (hazard ratio 0.54, 95% confidence interval 0.3–0.97). Thirteen patients (9%) experienced progression in the prostate and nine (6%) showed extravesical progression (upper urinary tract or metastases). This was independent of BCG treatment. Conclusion. CIS in the absence of invasive (T1) disease carried a 10-year risk of progression of 29–48%. Although BCG was effective against CIS, this effect was limited to the bladder. BCG provided a marginal, but significant reduction in the overall long-term risk of progression.
- 27 July 2011
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 45 (6) , 411-418
Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette–Guérin immunotherapy on the outcome
Objective. This study aimed to determine the long-term risk of cancer progression of carcinoma in situ (CIS) of the urinary bladder, and whether intravesical bacille Calmette–Guérin (BCG) immunotherapy can reduce the risk of progression of CIS.Material and methods. From a prospectively enrolled cohort of bladder cancer patients treated at Århus University Hospital Skejby, Denmark, between 1994 and 2008, all 163 cases with CIS in the bladder, and a history free of invasive bladder cancer (stage T1–4) at least 1 year prior to inclusion were included in the study. Results. Median follow-up was 51 (0–253) months for progression. Initial treatment consisted of transurethral resection (TUR) alone (109 patients) or TUR plus BCG (54 patients). Twenty-eight patients underwent delayed treatment with BCG. Twenty-one patients in the TUR-alone group (19%) and 42 BCG-treated patients (51%) were free of disease at the end of follow-up (p < 0.001). Progression occurred in 18 BCG-treated patients (22%) versus 31 patients (41%) treated by TUR alone. The 10-year progression-free survival was 62% overall, 50% without BCG and 71% after BCG treatment (p = 0.04). BCG reduced the risk of progression by 46% (hazard ratio 0.54, 95% confidence interval 0.3–0.97). Thirteen patients (9%) experienced progression in the prostate and nine (6%) showed extravesical progression (upper urinary tract or metastases). This was independent of BCG treatment. Conclusion. CIS in the absence of invasive (T1) disease carried a 10-year risk of progression of 29–48%. Although BCG was effective against CIS, this effect was limited to the bladder. BCG provided a marginal, but significant reduction in the overall long-term risk of progression.
- Open Access
- 24 November 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 646
Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts
Background: Identification of urinary biomarkers for detection of bladder cancer recurrence would be beneficial to minimize the frequency of cystoscopy. Our objective was to determine the usability of urine content of mRNA in the detection and prediction of bladder cancer recurrence. Methods: We analyzed 123 prospectively cross-sectional collected urine samples from 117 patients with bladder cancer (12 incident cancers and 111 control visits). We used biopsies from cystoscopies as diagnostic criteria for recurrence, and followed the patients for a median time of 28.5 months (range 0-44 months). We measured the levels of hTERT, SENP1, PPP1CA, and MCM5 mRNA in urine by q-RT- PCR. Results: We found significant differences in urinary content of hTERT (p < 0.001), SENP1 (p < 0.001), MCM5 (p < 0.001), and PPP1CA (p < 0.001) transcripts, when comparing urine samples from patients with and without tumor present in the bladder. We obtained sensitivity and specificity values for hTERT: 63/73, SENP1: 56/78, MCM5: 63/66, and PPP1CA: 69/63, respectively. Including follow-up data resulted in sensitivity and specificity values for hTERT: 62/84, SENP1:53/84, MCM5: 61/73, and PPP1CA: 65/66. Interestingly, at non-tumor visits the urinary content of especially hTERT (p = 0.0001) and MCM5 (p = 0.02) were significantly associated with subsequent tumour recurrence. Combining the markers with cytology improved the detection. The best combination was hTERT and cytology with a sensitivity of 71% and a specificity of 86% after follow-up. Further prospective validation or registration studies needs to be carried out before clinical use. Conclusions: We could use the urinary content of hTERT, SENP1, PPP1CA, and MCM5 to detect bladder cancer recurrence. All markers showed a higher sensitivity than cytology. The detection rate improved when including cytology results, but also the combination of hTERT and MCM5 increased the detection rate. Furthermore, hTERT and MCM5 levels predicted subsequent tumor recurrences.
- 24 November 2010
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 646
Open AccessPrediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts
Background: Identification of urinary biomarkers for detection of bladder cancer recurrence would be beneficial to minimize the frequency of cystoscopy. Our objective was to determine the usability of urine content of mRNA in the detection and prediction of bladder cancer recurrence. Methods: We analyzed 123 prospectively cross-sectional collected urine samples from 117 patients with bladder cancer (12 incident cancers and 111 control visits). We used biopsies from cystoscopies as diagnostic criteria for recurrence, and followed the patients for a median time of 28.5 months (range 0-44 months). We measured the levels of hTERT, SENP1, PPP1CA, and MCM5 mRNA in urine by q-RT- PCR. Results: We found significant differences in urinary content of hTERT (p < 0.001), SENP1 (p < 0.001), MCM5 (p < 0.001), and PPP1CA (p < 0.001) transcripts, when comparing urine samples from patients with and without tumor present in the bladder. We obtained sensitivity and specificity values for hTERT: 63/73, SENP1: 56/78, MCM5: 63/66, and PPP1CA: 69/63, respectively. Including follow-up data resulted in sensitivity and specificity values for hTERT: 62/84, SENP1:53/84, MCM5: 61/73, and PPP1CA: 65/66. Interestingly, at non-tumor visits the urinary content of especially hTERT (p = 0.0001) and MCM5 (p = 0.02) were significantly associated with subsequent tumour recurrence. Combining the markers with cytology improved the detection. The best combination was hTERT and cytology with a sensitivity of 71% and a specificity of 86% after follow-up. Further prospective validation or registration studies needs to be carried out before clinical use. Conclusions: We could use the urinary content of hTERT, SENP1, PPP1CA, and MCM5 to detect bladder cancer recurrence. All markers showed a higher sensitivity than cytology. The detection rate improved when including cytology results, but also the combination of hTERT and MCM5 increased the detection rate. Furthermore, hTERT and MCM5 levels predicted subsequent tumor recurrences.
- Open Access
- 2 June 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2095-2103
Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development
Bladder cancer develops through different pathways, provisionally entitled “papillary” and “invasive.” Carcinoma in situ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these clinically important lesions, and the relationship between chromosomal alterations and the different pathways. We laser‐microdissected 12 CIS and 4 dysplasia samples concomitant to invasive bladder cancer. We determined genome‐wide chromosome copy number changes and loss of heterozygosity (LOH) using Mapping 10K SNP microarrays. We further examined 48 high‐risk non‐muscle‐invasive bladder cancers using SNP microarrays to reveal characteristic changes correlated with the CIS‐phenotype. DNA copy‐number changes were further validated using QPCR in 77 independent tumor samples. CIS was found to be chromosomal unstable in 8 of 12 cases. Characteristic chromosomal changes were copy number gains of chromosomes 5p, 6p22.3, 10p15.1 and losses/LOH of chromosome 5q and 13q13‐q14. Tumor samples with these alterations were significantly associated with CIS. Using FGFR3 mutations as markers of the opposing papillary phenotype, we found 5p gains and FGFR3 mutations mutually exclusive. No FGFR3 mutations were found in 23 CIS and dysplasia samples. Based on this, we classified high‐risk non‐muscle‐invasive bladder tumors according to FGFR3 mutations and chromosomal changes into papillary and CIS‐type tumors with high correlation to CIS status (p = 0.001). Furthermore, we found significant correlation to the results of molecular classifiers based on gene‐expression. We concluded that chromosomal changes may be used to characterize different pathways in bladder cancer development. © 2009 UICC
- 2 June 2009
- Published by Wiley in International Journal of Cancer
- Vol. 125 (9) , 2095-2103
Open AccessConsistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development
Bladder cancer develops through different pathways, provisionally entitled “papillary” and “invasive.” Carcinoma in situ (CIS) is thought to be the precursor of invasive bladder cancer. However, little is known about chromosomal alterations of these clinically important lesions, and the relationship between chromosomal alterations and the different pathways. We laser‐microdissected 12 CIS and 4 dysplasia samples concomitant to invasive bladder cancer. We determined genome‐wide chromosome copy number changes and loss of heterozygosity (LOH) using Mapping 10K SNP microarrays. We further examined 48 high‐risk non‐muscle‐invasive bladder cancers using SNP microarrays to reveal characteristic changes correlated with the CIS‐phenotype. DNA copy‐number changes were further validated using QPCR in 77 independent tumor samples. CIS was found to be chromosomal unstable in 8 of 12 cases. Characteristic chromosomal changes were copy number gains of chromosomes 5p, 6p22.3, 10p15.1 and losses/LOH of chromosome 5q and 13q13‐q14. Tumor samples with these alterations were significantly associated with CIS. Using FGFR3 mutations as markers of the opposing papillary phenotype, we found 5p gains and FGFR3 mutations mutually exclusive. No FGFR3 mutations were found in 23 CIS and dysplasia samples. Based on this, we classified high‐risk non‐muscle‐invasive bladder tumors according to FGFR3 mutations and chromosomal changes into papillary and CIS‐type tumors with high correlation to CIS status (p = 0.001). Furthermore, we found significant correlation to the results of molecular classifiers based on gene‐expression. We concluded that chromosomal changes may be used to characterize different pathways in bladder cancer development. © 2009 UICC
- Open Access
- 16 May 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 149
Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Non-muscle invasive bladder neoplasms with invasion of the lamina propria (stage T1) or high grade of dysplasia are at "high risk" of progression to life-threatening cancer. However, the individual course is difficult to predict. Chromosomal instability (CI) is associated with high tumor stage and grade, and possibly with the risk of progression.
- 16 May 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 149
Open AccessChromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer
Non-muscle invasive bladder neoplasms with invasion of the lamina propria (stage T1) or high grade of dysplasia are at "high risk" of progression to life-threatening cancer. However, the individual course is difficult to predict. Chromosomal instability (CI) is associated with high tumor stage and grade, and possibly with the risk of progression.
- Open Access
- 8 December 2007
- Published by Wiley in Molecular Oncology
- Vol. 1 (4) , 384-394
High throughput molecular diagnostics in bladder cancer - on the brink of clinical utility
An enormous body of high‐throughput genome‐wide data, in particular gene expression data, has been gathered from roughly all human cancer forms in the past 10years. This has widely increased our understanding of the cancer disease and its molecular changes and pathways, with a large contribution from studies of cancer cell lines and functional genomics. In the last three years, the focus has been moved to clinical outcome parameters as recurrence, progression, metastasis and treatment response. The huge variability of molecular changes and poor availability of samples have hampered progress in the field of epithelial cancer (carcinoma). However, independent validation of molecular profiles across high‐throughput platforms, methods, laboratories and cancer populations has recently been successfully performed for several carcinomas, including bladder cancer. Application of advanced bioinformatics to identify interrelated pathways has revealed common signatures predictive of molecular subgroups, improving histopathological diagnosis, and ultimately outcome prediction. With breast cancer leading the field, colorectal, bladder and renal cell carcinomas well on their way, and many others soon to join, the era of clinical applications of high‐throughput molecular methods in cancer lies closely ahead. This review illustrates in detail the perspectives for the management of bladder cancer.
- 8 December 2007
- Published by Wiley in Molecular Oncology
- Vol. 1 (4) , 384-394
Open AccessHigh throughput molecular diagnostics in bladder cancer - on the brink of clinical utility
An enormous body of high‐throughput genome‐wide data, in particular gene expression data, has been gathered from roughly all human cancer forms in the past 10years. This has widely increased our understanding of the cancer disease and its molecular changes and pathways, with a large contribution from studies of cancer cell lines and functional genomics. In the last three years, the focus has been moved to clinical outcome parameters as recurrence, progression, metastasis and treatment response. The huge variability of molecular changes and poor availability of samples have hampered progress in the field of epithelial cancer (carcinoma). However, independent validation of molecular profiles across high‐throughput platforms, methods, laboratories and cancer populations has recently been successfully performed for several carcinomas, including bladder cancer. Application of advanced bioinformatics to identify interrelated pathways has revealed common signatures predictive of molecular subgroups, improving histopathological diagnosis, and ultimately outcome prediction. With breast cancer leading the field, colorectal, bladder and renal cell carcinomas well on their way, and many others soon to join, the era of clinical applications of high‐throughput molecular methods in cancer lies closely ahead. This review illustrates in detail the perspectives for the management of bladder cancer.